News

Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key ...
BioSpace55m
Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...